This study concludes that HVEM expression is upregulated in many types of cancer, including CML and ALL, and HVEM protein acts as an immune suppressive molecule that contributes to tumor progression and may serve as a potential biomarker and target for cancer immunotherapy. Here, TNFRSF14 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.